Latest Breakthrough nod goes to Novartis

Share this article:

The FDA announced Tuesday that it has approved the Novartis lung cancer drug Zykadia, or ceritinib (previously known as LDK378).

The approval is for patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC), specifically those who were previously treated with Pfizer's Xalkori (crizotinib). Xalkori is the only other approved ALK tyrosine kinase inhibitor but one which (like many molecular targeted drugs) encounters resistance.

The approval is the fourth drug with the FDA's Breakthrough Therapy designation to be approved by the agency.

The drug is also considered an orphan product and is notable for its approval speed: the approval deadline was August 24, four months from now.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.